Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma
Jason Luke, MD
Published: Thursday, Oct 19, 2017
Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.
There are early-phase data with pembrolizumab (Keytruda) and epacadostat showing that adding the IDO inhibitor improved the response rate to pembrolizumab monotherapy from 40% to 55%, explains Luke. There was no increased toxicity observed in this combination.
A phase III trial investigating this combination compared with a placebo-controlled pembrolizumab monotherapy has completed accrual. According to Luke, this combination could change the standard of care for patients with melanoma.
Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.
There are early-phase data with pembrolizumab (Keytruda) and epacadostat showing that adding the IDO inhibitor improved the response rate to pembrolizumab monotherapy from 40% to 55%, explains Luke. There was no increased toxicity observed in this combination.
A phase III trial investigating this combination compared with a placebo-controlled pembrolizumab monotherapy has completed accrual. According to Luke, this combination could change the standard of care for patients with melanoma.